AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced that its automated device, RECELL GO, maintains the Food and Drug Administration (FDA) Breakthrough Device designation for the treatment of acute wounds. RECELL GO represents an evolution of the existing RECELL technology and is designed to automate the process of cell disaggregation.
“RECELL GO is a critical component of our platform, and we believe it will greatly accelerate our growth,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Automating the disaggregation process will substantially reduce training requirements, allowing us to leverage selling time more effectively. Additionally, it will ease the burden on physicians and operating room staff, leading to increased adoption. Our dedication to our automation program reflects our continued commitment to innovation and patient care.”
CIO INFLUENCE: PlainID Launches The PlainID Technology Network to Enable Identity Aware Security for Advanced Access Control
As previously announced, AVITA Medical plans to submit a Premarket Approval (PMA) supplement to the FDA for RECELL GO by June 30, 2023. Under the Breakthrough Device program, the submission will receive prioritized, interactive review with an expected January 2024 approva
AVITA Medical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including soft tissue repair and repigmentation of stable vitiligo lesions.
AVITA Medical’s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.
CIO INFLUENCE: Ascend.io Launches Solution in Partnership with Snowflake, Enabling Cost Savings for Data Teams
[To share your insights with us, please write to sghosh@martechseries.com]
